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Background. The incidence of acute rejection is considered to
be higher after simultaneous pancreas-kidney (SPK) transplanta-
tion as compared to renal transplant alone. Therefore, the
majority of SPK transplant recipients commonly receive a combi-
nation of cyclosporine (CsA) or tracolimus, and azathioprine or
mycophenolic mofetyl, corticosteroids and/or antilymphocyte
preparations. This study was designed to compare two immuno-
suppressive protocols for the prevention of acute rejection in
patients undergoing SPK transplantation. The primary end-point
was the incidence of acute rejection during the first 12 months
after transplantation
Methods. Fifty patients with type-I insulin-dependent diabetes
and chronic renal failure were randomized to receive a triple drug
immunosuppressive regimen including CsA, azathioprine and
corticosteroids (N 5 25), or the quadruple sequential combina-
tion of rabbit antithymocyte globulin (ATG) given for 10 days,
azathioprine, corticosteroids and delayed CsA (N 5 25). Mainte-
nance immunosuppression (CsA and azathioprine, without corti-
costeroids) was similar in both arms.
Results. The average follow-up was 36 months in both groups
(range 9 to 60 months). No patient was excluded from the study.
Although the percentage of patients with adverse events was
higher in the ATG group (80 vs. 40%, P , 0.01), none of them
resulted in premature discontinuation of the drug. Patients receiv-
ing ATG experienced a lower incidence (36% vs. 76%, P , 0.01)
and number (13 vs. 29, P , 0.05) of acute renal rejection episodes.
However, no difference was observed in patient, pancreas and
kidney survival rates between groups. No case of isolated pancreas
rejection was observed.
Conclusions. The quadruple sequential combination ATG, aza-
thioprine, corticosteroid and CsA significantly reduced the one
year incidence of acute renal rejection after SPK transplantation,
compared to a triple immunosuppressive regimen.
The first human pancreas transplant was performed in
1966 [1]. To date, more than 9,000 transplants have been
reported in the International Pancreas Transplant Registry.
In the great majority of cases, pancreas transplantation is
performed simultaneously with a kidney transplant for the
treatment of end-stage renal failure secondary to type I
diabetes. Several investigators have reported a higher inci-
dence of acute rejection of the kidney in simultaneous
pancreas-kidney (SPK) recipients than kidney transplant
alone recipients [2–8]. Therefore, SPK transplant recipi-
ents have traditionally been given more immunosuppres-
sion. As a result of this, quadruple induction immunosup-
pression followed by a triple therapy regimen is the
standard treatment for SPK transplanted patients [9–13].
This regimen includes a combination of a calcineurin
inhibitor (CsA or tacrolimus), an anti-metabolite (azathio-
prine or mycophenolic mophetil), corticosteroids and poly-
clonal or monoclonal antilymphocyte antibodies. A large
part of the immunosuppression data for pancreas trans-
plantation has not been derived from prospective random-
ized studies. In fact, to our knowledge, there are only two
reports of a randomized trial testing of the immunosup-
pressive protocols in pancreas transplantation [14, 15].
Therefore, precise comparisons of immunosuppressive pro-
tocols for SPK transplantation are lacking. We previously
reported that quadruple immunosupression with antithy-
mocyte globulin (ATG), cyclosporine A (CsA), azathio-
prine and corticosteroids in SPK transplants resulted in a
20% acute rejection rate [16, 17].
The present study compares the effectiveness of two
well-known immunosuppressive protocols for the preven-
tion of acute rejection in patients undergoing SPK trans-
plantation.
METHODS
Patients
All patients in this study underwent SPK transplantation
for the treatment of end-stage renal failure secondary to
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type I diabetes (basal and stimulated negative plasma
C-peptide). Fifty eligible patients were randomized, 25 in
each therapeutic arm. Both groups had similar demo-
graphic data (Table 1).
Study design and end-point
The study was prospective, single center, open label,
randomized trial. Between September 1992 and February
1997, 50 patients (22 women and 28 men) from whom
informed consent had been obtained were enrolled in this
study. The mean age was 41 years with a range of 24 to 53
years (Table 1). All patients were recipients of a first SKP
transplantation. The patients were randomized within a 24
hour period prior to surgery. The randomization method
used involved envelopes that contained either of the two
treatment groups. Prior to randomization the patients were
stratified according to age (,50 or .50 years) and percent
of anti-HLA alloantibodies (,50% or .50% anti-T lym-
phocyte random panel reactivity).
The primary end-point was acute renal rejection (inten-
tion to treat and/or histologically confirmed), as well as the
number of clinically suspected pancreas acute rejection
episodes during the first 12 months post-transplant. When
an acute rejection episode of the kidney was suspected, a
percutaneous kidney biopsy was always performed. All
rejection episodes were histologically confirmed by one of
two pathologists blinded to the treatment group. The
severity was graded according to the Banff score [18]. No
pancreas histology was available, since pancreas biopsies
were not performed. Pancreas rejection was defined as an
increased basal or stimultated glycemia above 10 and 15
mmol/liter, respectively.
Secondary end-points included graft loss, death with or
without functioning grafts, infections and malignacies. Cy-
tomegalovirus (CMV) infection was defined as a syndrome
including fever (.38°C), asthenia and leukopenia [white
blood cell count (WBCC) ,3,000 mm3], and always con-
firmed by CMV viremia [19]. All the patients with CMV
infection received intravenous ganciclovir (Cymevan®;
Hoffman-La Roche, France) for two weeks.
Treatment
Patients allocated to the non-ATG group were started on
intravenous CsA (Sandimmune®; Sandoz, Rueil-Malmai-
son, France) immediately after surgery at an initial dose of
3 mg/kg daily. When oral nutrition was possible (around
day 3), CsA was given at an initial dose of 10 mg/kg (in 2
divided doses). Thereafter, CsA dosing was adjusted to
maintain a whole-blood CsA trough level between 200 and
300 ng/ml. CsA trough level was measured daily before the
morning dose by a specific monoclonal radioimmunoassay
kit (Cyclo-trac®; Incstar Corporation, MN, USA). A con-
centration greater than 300 ng/ml resulted in a dose
reduction by 50 mg/day until the target CsA trough level
was achieved. On the other hand, the dose was increased by
50 mg if trough levels were lower than 200 ng/ml. CsA dose
adjustments were done independently of the renal or
pancreas allograft function. Concomitant with CsA, aza-
thioprine (Imurel®; Wellcome SA, Issy-les-Moulineaux,
France) was given immediately after surgery at an initial
intravenous dose of 2 mg/kg daily. A similar oral dose was
given when oral nutrition was possible and dose adjust-
ments were performed according to WBCC. In cases of
severe leukopenia (that is, WBCC ,3.000/mm3), azathio-
prine was discontinued until normalization of the WBCC.
Finally, 1 mg/kg of methylprednisolone (Solu-me´drol®;
Laboratoires Upjohn, Paris-La De´fense, France) was given
daily the first two postoperative days, followed by 0.5 mg/kg
daily of oral prednisone (Cortancyl®; Laboratoires Rous-
sel, Paris, France) for the next two days, and subsequently
tapered and withdrawn on post-operative day 45 [20].
The ATG group received the same azathioprine and
corticosteroid regimen as patients in the non-ATG group.
Rabbit ATG (Thymoglobuline®; Pasteur Me´rieux Con-
naught, Transplantation, Lyon, France) was given immedi-
ately after surgery instead of CsA. The initial dose of ATG
was 1.5 mg/kg daily followed by daily dose adjustments (if
Table 1. Demographic data
Non-ATG group
(N525)
ATG group
(N525) P value
Number of male/female
recipients
17/8 11/14 NS
Mean age years 39 43 NS
range 24–51 33–53
Patients .50 years 2 (8%) 2 (8%) NS
Duration of diabetes years 26.4 30.5 NS
range 14–37 13–46 NS
Patients with pre-transplant
blood transfusions
24 (96%) 24 (96%) NS
Patients with anti-HLA
alloantibodies .50%
1 (4%) 0 NS
B-cell positive crossmatcha 1 (4%) 0 NS
CMV positive patients 7 (28%) 8 (32%) NS
Number of cadaver donors 25 25 NS
Donor’s mean age years 32 29.5 NS
range 18–50 15–54
Male donors 19 (76%) 20 (80%) NS
CMV positive donorsb 6 (24%) 5 (20%) NS
Pre-emptive transplantationc 6 (24%) 8 (32%) NS
Mean renal cold ischemia
time minutes
680 730 NS
range 240–1180 288–1140
Mean pancreas cold ischemia
time minutes
646 630 NS
range 240–1020 240–1080
Mean donor/recipient
HLA-A-B-DR mismatch
3.8 4.2 NS
range 1–6 2–6
Abbreviations are: ATG, antithymocyte globulin; CMV, cytomegalovi-
rus. NS denotes statistically not significant.
a Patients who were transplanted against a positive B-lymphocyte
crossmatch.
b Positive IgG anti-CMV serology
c Patients transplanted before being treated with chronic dialysis and
with a serum creatinine level higher than 300 mmol/liter.
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necessary) in order to maintain the percentage of T-
lymphocytes forming rosettes with sheep’s erytrocytes (ro-
setting test) below 10% [21]. ATG was perfused during six
to ten hours through a central vein or into the arterio-
venous fistula utilized for hemodialysis. The duration of
ATG treatment was 10 days. In this group, oral CsA was
started on post-operative day 9, at a similar oral dose than
previously described. ATG and CsA were not given simul-
taneously, in order to avoid the potential risk of over-
immunosuppression and to optimize the rationale of the
induction regimen, since CsA may block some of the
long-term beneficial effects of ATG [22].
In the absence of contraindication, acute rejection was
treated with OKT3 (Orthoclone OKT3®; Laboratoires
Cilag, Levallois Perret, France). Five milligrams of OKT3
were to be infused intravenously daily for 10 days. One
hour before the first and second injection of OKT3, 3 to 5
mg/kg of methylprednisolone were given in order to de-
crease the OKT3-induced cytokine-release syndrome [23].
CsA was discontinued during the first seven days of OKT3
treatment, and reintroduced on day 8. A rejection episode
resistant to this treatment (no amelioration of the renal
function at the end of the course of OKT3 with persistence
of histological lesions of rejection), or new rejections were
to be treated with high-dose, intravenous methylpred-
nisolone (5, 5, 4, 3, and 2 mg/kg daily for 5 consecutive
days) or ATG.
In addition to the immunosuppressive drugs, patients in
both groups received standard prohylactic treatments con-
sisting of famotidine (20 mg daily for1 month), aluminium
hydroxide (1.275 mg daily for1 month), subcutaneous hep-
arin (0.3 ml twice daily for 3 to 7 days), aspirin (100 mg
daily) and dipyridamol (300 mg daily). If necessary, exog-
enous subcutaneous or intravenous insulin was given post-
transplantation in order to maintain a blood glucose con-
centration below 10 mmol/liter. No prophylactic anti-viral
therapies were given.
Surgical procedure
All transplants were from cadaver donors, and the
pancreas were transplanted according to the surgical pro-
cedure originally described by Dubernard et al [24]. Surgi-
cal complications and long-term results with this technique
in our center have been reported [25, 26]. This technique
attempts to suppress the exocrine pancreatic secretion.
Briefly, the body and tail of the pancreas is used for
transplantation. The exocrine secretions are managed by
ductal injection with 3 to 8 ml of a synthetic liquide rubber
(Neoprene®; Laboratoire Dupont, Paris, France). This
substance becomes solid in the presence of the exocrine
secretions. The prepared pancreas was implanted retroper-
itoneally in the right iliac vessels. The kidney was then
implanted via a second incision on the left iliac vessels also
in the retroperitoneum.
Statistical anlysis
Statistical analysis was performed using the Student’s
t-test for unpaired variables between groups, the Cochran-
Mantel-Haenzel test was used to estimate the risk ratio,
confidence intervals for the risk difference were calculated
by the Cox model test, and the Chi-square or the Fischer’s
exact tests was used for categoric parameters. Survival
curves were estimated by the Kaplan-Meier product limit
method, and statistical significance was assessed by the
Mantel-Cox log rank test. P values less than 0.05 were
accepted as statistically significant.
RESULTS
Donor data, and recipient age, sex, CMV status, duration
of diabetes, previous transfusions, anti-HLA alloantibodies
.50%, cold ischemia time and HLA-match were similar in
both groups (Table 1). Six patients (24%) in the non-ATG
group and eight patients (32%) in the ATG group were not
yet on chronic dialysis at the time of transplantation. All
but one pancreas grafts functioned immediately with pro-
duction of C-peptide levels. Two kidneys in the non-ATG
treatment arm experienced delayed graft function defined
by the requirement of transient hemodialysis. Post-trans-
plant follow-up did not differ between the two randomized
groups (average of 36 months for patients in the non-ATG
group and 36.4 months for patients in the ATG group).
Efficacy analysis
No patient was lost to follow-up. Biopsy confirmed acute
renal rejection was greater in the non-ATG group (19 out
of 25, 76%; vs. 9 out of 25, 36%; P , 0.01; risk ratio 4.79,
CI 1.75 to 13.09; Table 2). Among the eight patients with
repeated rejection in the non-ATG group, six had the first
rejection episode during the first 15 post-transplant days.
Among the four patients with repeated rejection in the
ATG group, none had a rejection episode during the first
15 post-transplant days. The time to the first renal acute
rejection was also significantly shorter (P , 0.05) in the
non-ATG group (average 20 days, range 7 to 85), compared
to the ATG group (30 days, range 10 to 60). All first
Table 2. Acute rejection episodes
Non-ATG group
(N525)
ATG group
(N525) P value
Number of rejection episodes 29 13 ,0.05
Patients with acute rejection 19 (76%) 9 (36%) ,0.01
First rejection ,15 days 9 1 ,0.002
First rejection 16–90 days 9 8 ,0.002
First rejection 91–180 days 1 0 ,0.002
Borderline rejections 7 3 NS
Grade 1 rejections 20 5 NS
Grade 3 rejections 1 5 NS
Abbreviation ATG is antithymocyte globulin. Rejection episodes were
restricted to the kidney transplant and were all histologically confirmed
and graded according to the Banff classification. NS denotes not signifi-
cant.
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rejection episodes but one occurred during the first three
post-transplant months in both groups. Throughout the
first post-transplant year, a statistically significant (P ,
0.05) higher number of renal rejection episodes was still
observed among patients from the non-ATG group (N 5
29; 1.16 rejection per patient) as compared to patients from
the ATG group (N 5 13; 0.52 rejection per patient). All
first rejection episodes in the non-ATG group were treated
with OKT3, while only three out of nine from the ATG
group received OKT3. The remaining six patients with
rejection received high dose corticosteroids because of
clinical contraindication to receive OKT3.
Histological examination of renal biopsies showed that
83% of the acute rejection episodes were borderline or
grade 1, while six (14%) were classified as grade 3. Five
from these six severe histological rejections were observed
in the ATG group (in 2 cases concomitantly with an
ATG-related acute serum sickness) and one in the non-
ATG group. Four episodes were completely reversible
(return to pre-rejection creatinine level) under standard
antirejection treatment, while two patients (one in the
ATG group and one in the non-ATG group) lost their
grafts.
No case of isolated pancreas rejection was clinically
suspected. Measurement of fasting blood glucose and C-
peptide concentrations did not change significantly during
the onset of renal rejection in any case (data not shown).
Fourteen pancreas (28%) were lost, seven in the non-
ATG group (4 hemorragic infected pancreatitis, 1 vein
thrombosis and 2 from unknown causes) and seven in the
ATG group (2 hemorragic infected pancreatitis, 1 vein
thrombosis, 1 hyperacute rejection, 1 graft with primary
nonfunction, 1 unknown cause and 1 death). Seven kidneys
were lost (14%), five in the non-ATG group (4 chronic
rejections and 1 death) and two in the ATG group (1
hyperacute rejection and 1 death).
Three patients died (6%): one patient in the non-ATG
group died because of a pulmonary infection 18 months
after transplantation, and two patients in the ATG group
died because of sepsis, one month after removal of the two
rejected organs, and one secondary a leg amputation 15
months after transplantation. No statistical differences
were noted concerning the patient, pancreas and kidney
graft survival rates (Fig. 1).
Only two patients in the non-ATG group had serum
creatinine levels greater than 200 mmol/liter at one year.
This explains the higher one year serum creatinine in this
group (159 vs. 128 mmol/liter; P , 0.03). Fasting blood
glucose concentrations were similar in the two groups at
one year (5.7 mmol/liter in the non-ATG group and 5.6
mmol/liter in the ATG group), and all patients with func-
tioning pancreas had a concentration of A1C glycated
hemoglobin less than 7%.
Safety analysis
In the ATG group, 20 (80%) patients experienced one or
more adverse events versus 10 (40%) in the non-ATG
group (P , 0.01). None of them resulted in premature
discontinuation of ATG. Leukopenia (WBC ,4.000/mm3)
and fever were the main side effects observed in ATG
treated patients (Table 3). Because of this, five patients in
the ATG group required transient discontinuation of aza-
thioprine versus one patient in the non-ATG group. No
case of agranulocytosis was noted in any of the two groups.
Fig. 1. Kaplan-Meier patient (A), pancreas (B), and kidney survival (C)
rates after simultaneous pancreas-kidney (SPK) transplantation. Survival
rates did not statistically differ (log rank test P , 0.9 for patient, 0.9 for
pancreas and 0.3 for kidney survival, respectively) between patients
receiving prophylactic antithymocyte globulin (ATG), azathioprine, corti-
costeroids and delayed introduction of cyclosporine A (CsA; ATG group),
or triple therapy induction with immediate CsA, azathioprine and corti-
costeroids, without ATG (non-ATG group). Symbols are: ( ) ATG
group; (— —) non-ATG group.
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Three patients developed reversible ATG-induced acute
serum sickness.
Opportunistic infections were more frequent (but not
statistically significant) in the ATG group (Table 3). The
majority of bacterial infections were related to peripancre-
atic fluid collections and/or pancreatic fistulas. CMV infec-
tions were more frequent in the ATG group (60 vs. 40%;
P , 0.08). In the non-ATG group, four patients received
ATG for rejection rescue therapy, and three from these
four patients (75%) experienced CMV infection. In con-
trast, among the 21 patients not receiving additional ATG
for rejection, the incidence of CMV was 33.3%. From the
six patients free of rejection, only one (17%) experienced
CMV infection. In the ATG group, seven patients had a
rejection episode before CMV infection and eight patients
had a CMV infection without previous rejection. From the
16 patients free of rejection, eight (50%) had a CMV
infection.
No malignant disorder was observed.
DISCUSSION
The most important finding of this study is that 10-day
induction treatment with rabbit ATG, azathioprine and
corticosteroids, followed by CsA introduction at the end of
the ATG course, significantly reduced the incidence and
number of acute renal rejection episodes when compared
to the triple drug association including immediate post-
operative CsA, azathioprine and corticosteroids, without
ATG induction. The incidence of acute rejection in the
ATG group (36%) was similar to that observed previously
in a nonrandomized study [27]. This incidence is also
similar to that observed in our center in non-diabetic
recipients of primary cadaver renal transplants alone who
received a similar immunosuppressive therapy [28]. These
results suggest that with ATG-induction, the addition of a
pancreas graft to a kidney transplantation does not increase
the magnitude of the immune response.
Patients in the non-ATG group had a significantly higher
incidence of acute renal rejection episodes, which required
the use of OKT3 or ATG. However, these rejection epi-
sodes were not more severe according to the Banff classi-
fication. At the time of the diagnosis of acute rejection,
CsA blood trough levels were within the target therapeutic
range, indicating that the usually recommended CsA blood
trough level might not be sufficient in the management of
this drug in patients with SKP transplants. As we and others
previously reported [29, 30], SKP transplant patients re-
quired more CsA than renal transplant recipients to
achieved similar CsA blood trough concentration. Whether
a greater CsA trough level should be targeted in SKP
transplant patients than in patients with a single renal
transplant, and/or other blood measurement during the day
should be done, is yet to be determined. The recent
observation that the microemulsion formulation of CsA
(Neoral) reverses CsA malabsorption in a similar trans-
plant population [31, 32] suggests that the AUC could be
more effective than the CsA blood trough levels in the
management of this drug in this particular population. A
better monitoring of this drug will probably decrease the
number of rejection episodes in the future. However, all the
patients in this study received intravenous CsA for the first
three to four postoperative days, so far avoiding potential
initial CsA malabsorption.
Despite a greater frequency of hematological adverse
events (mainly transient leukopenia), observed in the ATG
group, all the patients were able to receive the entire 10-day
course. Although both treatment groups in this study were
well balanced for pretransplant CMV serostatus of donor
and recipient, and despite less antirejection courses of
OKT3, there was a trend towards a higher incidence of
CMV infection in patients receiving ATG. This observation
is concordant with previous reports in which ATG treat-
ment was found to be associated with more CMV infections
than triple therapy or even OKT3 [33, 34].
Although the incidence of renal acute rejection was
higher in the non-ATG group, renal graft survival did not
differ compared to patients who received ATG induction
therapy. One possible explanation of this unexpected find-
ing could be related to the fact that all first rejections in the
in the non-ATG group were treated with OKT3 as first-line
therapy while only three from nine patients in the ATG
group received OKT3. However, since 100% renal graft
survival was observed in patients free of rejection in both
groups, one may suggest that the acute rejection effect may
become significant in a larger cohort of patients with longer
follow-up.
In conclusion, this controlled study demonstrates that
prophylaxis with ATG significantly reduces the incidence of
acute renal rejection epsiodes after SPK transplantation.
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Table 3. Adverse events and infectious episodes during the first
12 post-transplant months
Non-ATG group
(N525)
ATG group
(N525) P value
Acute serum sickness 0 3 (12%) NS
Fever .38° 10 (40%) 15 (60%) NS
Leukopenia (,4.000 mm3) 3 (12%) 12 (48%) 0.005
Peripheral neuropathy 1 (4%) 3 (12%) NS
CMV infection 10 (40%) 15 (60%) NS
Urinary tract infection 4 (16%) 9 (36%) NS
Septicemia 2 (8%) 4 (16%) NS
Wound infection (pancreas site) 18 (72%) 18 (72%) NS
Abbreviations are: ATG, antithymocyte globulin; CMV, cytomegalovi-
rus. Number and percentage of adverse events and infectious episodes
occurring during the first year after transplantation. A total of 20 patients
in the ATG group had one or more adverse events versus 10 patients in
the non-ATG group (P,0.01).
a Fever and leukopenia noted during the first 15 post-transplant days.
Cantarovich et al: Treatment comparison in SPK transplantation 1355
Reprint requests to Diego Cantarovich, M.D., Institut de Transplantation et
de Recherche en Transplantation, Nantes University Hospital, 30 bd Jean
Monnet, 44000 Nantes, France.
E-mail: dcantaro@sante.inserm.fr
REFERENCES
1. KELLY WD, LILLEHEI RC: Allotransplantation of the pancreas and
duodenum along with the kidney in diabetic nephropathy. Surgery
61:827–833, 1967
2. RICHARDS KF, BELNAP GP, REES WV, STEVENS LE: Increased
incidence of kidney rejection episodes in patients receiving combined
kidney-pancreas transplants. (abstract) Diabetes 38:251, 1989
3. HILLEBRAND G, ILLNER WD, ABENDROTH D, SCHNEEBERGER H,
PETRY I, SCHLEIBNER S: Outcome of renal grafts after simultaneous
kidney/pancreas transplantation. Diabetologia 34:516–517, 1991
4. TESI RJ, HENRY ML, ELKHAMMAS EA, DAVIES EA, FERGUSON RM:
The frequency of rejection episodes after combined kidney-pancreas
transplant: The impact on graft survival. Transplantation 58:424–428,
1994
5. BOONSTRA JG, BRUIJN JA, LEMKES HHPJ, RINGERS J, VAN DEN PIJL
JW, VAN DEN WOUDE FJ: The incidence of interstitial and vascular
rejection after pancreas-kidney transplantation. J Am Soc Nephrol
5:1918–1925, 1995
6. DOUZDJIAN V, RICE JC, GUGLIUZZA KK, FISH JC, CARSON RW:
Renal allograft and patient outcome after transplantation: Pancreas-
kidney versus kidney-alone transplants in type 1 diabetic patients
versus kidney-alone transplants in nondiabetic patients. Am J Kidney
Dis 27:106–116, 1996
7. PIRSCH J, ANDREWS C, HRICIK DE, JOSEPHSON MA, LEICHTMAN AB,
LU CY: Pancreas transplantation for diabetes mellitus. Am J Kidney
Dis 27:444–450, 1996
8. SUTHERLAND DE: The case for pancreas transplantation. Diabetes
Metab 22:132–138, 1996
9. WADSTROM J, BREKKE B, WRAMMER L, EKBERG H, TYDEN G: Triple
versus quadruple induction immunosuppression in pancreas trans-
plantation. Transplant Proc 27:1317–1318, 1995
10. BARLETT ST, SCHWEITZER EJ, JOHNSON LB, KUO PC, PAPADIMITRIOU
JC, DRACHENBERG CB: Equivalent success of simultaneous pancreas
kidney and solitary pancreas transplantation: A prospective trial with
tracolimus immunosuppression with percutaneous biopsy. Ann Surg
224:440–449, 1996
11. GRUESSNER RWG, BURKE GW, STRATTA R, SOLLINGER H,
BENEDETTI E, MARSH CL: A multicenter analysis of the first experi-
ence with FK506 for induction and rescue therapy after pancreas
transplantation. Transplantation 61:261–273, 1996
12. KETEL BL, TURTON-WEEKS S, REED K, BARONE GW: Tracolimus-
based vs cyclosporine-based immunotherapy in combined kidney-
pancreas transplantation. (abstract) Transplant Proc 28:899, 1996
13. MELZER JS, D’ALESSANDRO AM, KALAYOGLU M, PIRSCH J, BELZER
FO, SOLLINGER HW: The use of OKT3 in combined pancreas-kidney
allotransplantation. Transplant Proc 22:634–635, 1990
14. CANTAROVICH D, LE MAUFF B, HOURMANT M, DANTAL J, BAATARD
R, DENIS M: Prevention of acute rejection episodes with an anti-
interleukin 2 receptor monoclonal antibody: Results after combined
pancreas and kidney transplantation. Transplantation 57:198–203,
1994
15. STRATTA RJ, TAYLOR RJ, WEIDE LG, SINDHI R, SUDAN D, CASTALDO
P: A prospective randomized trial of OKT3 vs. ATGAM induction
therapy in pancreas transplant recipients. Transplant Proc 28:917–918,
1996
16. CANTAROVICH D, PAINEAU J, HOURMANT M, BAATARD R, AUVIGNE J,
SOULILLOU JP: Low incidence of rejection following combined kidney
and pancreas transplantation. Transplant Proc 22:626–628, 1990
17. CANTAROVICH D, HOURMANT M, DANTAL J, GIRAL M, PAINEAU J,
KARAM G: Is the incidence of kidney rejection episodes higher in
combined kidney/pancreas than in single kidney transplant patients?
(abstract) Transplant Proc 26:535, 1994
18. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDIK JF, COHEN AH,
COLVIN RB: International standardization of criteria for the histologic
diagnosis of renal allograft rejection: The Banff working classification
of kidney transplanat pathology. Kidney Int 44:411–422, 1993
19. IMBERT-MARCILLE BM, CANTAROVICH D, FERRE-AUBINEAU V,
RICHET B, SOULILLOU JP, BILLAUDEL S: Usefulness of DNA viral load
quantification for CMV disease monitoring in renal and pancreas/
renal transplant recipients. Transplantation 63:1476–1481, 1997
20. CANTAROVICH D, PAINEAU J, KARAM G, MURAT A, BAATARD R,
DANTAL J: Definitive corticosteroid withdrawal following simulta-
neous pancreas and kidney transplantation. Transplant Proc 23:1583–
1584, 1991
21. SOULILLOU JP, CANTAROVICH D, LE MAUFF B, GIRAL G, HOURMANT
M, HIRN M: Randomized trial of an anti-interleukin 2 receptor
monoclonal antibody (33B3.1) versus rabbit antithymocyte globulin
(ATG) in prophylaxis of early rejection in human renal transplanta-
tion. N Engl J Med 322:1175–1182, 1990
22. OPELZ G: Efficacy of rejection prophylaxis with OKT3 in renal
transplantation. Transplantation 60:1220–1224, 1995
23. CHATENOUD L, FERRAN C, REUTER A, LEGENDRE C, GEVARET Y,
KREIS H: Systemic reaction to the anti-T cell monoclonal antibody
OKT3 in relation to serum level of tumor necrosis factor and
interferon alpha. N Engl J Med 320:1420–1421, 1989
24. DUBERNARD JM, TRAEGER J, NEYRA P, TOURAINE JL, TRANCHANT D,
BLANC-BRUNAT N: A new method of preparation of segmental
pancreas grafts for transplantation: Trials in dogs and in man. Surgery
84:633–639, 1978
25. PAINEAU J, CANTAROVICH D, COUDERC JP, LETESSIER E, BOUCHOT O,
KARAM G: Incidence du rejet apre`s transplantation pancre´atico-
re´nale. Chirurgie 117:357–363, 1991
26. CANTAROVICH D, KARAM G, GIRAL-CLASS M, HOURMANT M, DANTAL
J, BLANCHO G: Segmental duct-occluded pancreas transplantation:
9-year experience at a single institution. (abstract) Acta Diabetol 34:99,
1997
27. CANTAROVICH D, GIRAL M, JOSIEN R, KARAM G, HOURMANT M,
DANTAL J: Incidence and impact of acute rejection episodes on short-
and long-term graft survival in recipients of simultaneous pancreas-
kidney transplantation. (abstract) Transplant Proc 27:1319, 1995
28. GIRAL M, TADDEI C, NGUYEN JM, DANTAL J, HOURMANT M, CAN-
TAROVICH D: Analysis of 468 first cadaveric kidney allografts from a
single center with sequential therapy. Clin Transplant 21:257–264,
1996
29. CANTAROVICH F, BIZOLLON C, CANTAROVICH D, LEFRANCOIS N,
DUBERNARD JM, TRAEGER J: Cyclosporine plasma levels six hours
after oral administration: A useful tool for monitoring therapy.
Transplantation 45:389–394, 1988
30. CANTAROVICH D, DANTAL J, HOURMANT M, BAATARD R, PAINEAU J,
MURAT A: Importance of cyclosporine dosage and blood levels in
simultaneous pancreas and kidney transplant success. Transplant Proc
24:890–891, 1992
31. CHAPMAN JR, O’CONNELL PJ, BOVINGTON KJ, ALLEN RDM: Reversal
of cyclosporine malabsorption in diabetic recipients of simultaneous
pancreas and kidney transplants using a microemulsion formulation.
Transplantation 61:1699–1704, 1996
32. VAN DER PIJL JW, SRIVASTAVA N, DENOUE`L J, BURGGRAAF J,
SCHOEMAKER RC, VAN DEN WOUDE FJ: Pharmacokinetics of the
conventional and microemulsion formulations of cyclosporine in
pancreas-kidney transplant recipients with gastroparesis. Transplanta-
tion 62:456–462, 1996
33. SLAKEY DP, JOHNSON CP, CALLALUCE RD, BROWNE BJ, ZHU YR,
ROZA AM: A prospective randomized comparison of quadruple
versus triple therapy for first cadaver transplants with immediate
function. Transplantation 56:827–831, 1993
34. HANTO DW, JENDRISAK MD, SO SK, MCCULLOUGH CS, RUSH TM,
MICHALSKI SM: Induction immunosuppression with antilymphocyte
globulin or OKT3 in cadaver kidney transplantation. Results of a
single institution prospective randomized trial. Transplantation 57:
377–384, 1994
Cantarovich et al: Treatment comparison in SPK transplantation1356
